HIGHLIGHTS
- who: Peter McAllister from the Farm Road, Suite, Stamford, CT, USA have published the research work: Impact of Fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies, in the Journal: (JOURNAL)
- what: In this pooled analysis of data from patients with EM and CM, including those with difficult-to-treat migraine, fremanezumab demonstrated statistically significant and clinically meaningful improvements in headache- and migraine-related disability scores after 12 weeks of treatment.
- future: During a subsequent long-term extension study continued reductions in disability based . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.